[Pioglitazone].
Kobayashi
Masashi
M
First Department of Medicine, Toyama Medical and Pharmaceutical University.
Iwata
Minoru
M
Hiratani
Kazuyuki
K
D000818:Animals; D056486:Chemical and Drug Induced Liver Injury; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D004487:Edema / Q000139:chemically induced; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D007333:Insulin Resistance; D050356:Lipid Metabolism; D000077205:Pioglitazone; D018160:Receptors, Cytoplasmic and Nuclear / Q000502:physiology; D013844:Thiazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D045162:Thiazolidinediones; D014157:Transcription Factors / Q000502:physiology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000502:physiology
D007004:Hypoglycemic Agents; D018160:Receptors, Cytoplasmic and Nuclear; D013844:Thiazoles; D045162:Thiazolidinediones; D014157:Transcription Factors; D014409:Tumor Necrosis Factor-alpha; D000077205:Pioglitazone